Therapeutic administration of anti-PcrV F(ab′)2 in sepsis associated with Pseudomonas aeruginosa

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5880-5886

  Shime, N ^a   Sawa, T ^a   Fujimoto, J ^a   Faure, K ^a   Allmond, L R ^a   Karaca, T ^a   Swanson, B L ^a   Spack, E G ^a   Wiener Kronish, J P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; POLYCLONAL ANTIBODY; PROTEIN PCRV; PROTEIN PCRV ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HEMODYNAMICS; LUNG INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; SEPSIS; SEPTIC SHOCK; SURVIVAL;

EID: 0035889948     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5880     Document Type: Article

References (34)

1. Type III protein secretion systems in bacterial pathogens of animals and plants
2. Type III secretion machines: Bacterial devices for protein delivery into host cells
3. The exoenzyme S regulon of Pseudomonas aeruginosa
4. Prognostic factors of pneumonia requiring admission to the intensive care unit
5. Ventilator-associated pneumonia due to Pseudomonas aeruginosa
6. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: Analysis of 189 episodes
7. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: A multicenter prospective study in intensive care units: French ICU Group for Severe Sepsis
8. Pseudomonas aeruginosa-mediated cytotoxicity and invasion correlate with distinct genotypes at the loci encoding exoenzyme S
9. ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury
10. Exoproduct secretions of Pseudomonas aeruginosa strains influence severity of alveolar epithelial injury
11. In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections
12. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia
13. Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia
14. Type-111 protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections
15. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury
16. The Yersinia Yop virulon: A bacterial system for subverting eukaryotic cells
17. Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon
18. 1-capsule-positive and -negative strains of Yersinia pestis
19. V antigen-polyhistidine fusion peptide: Binding to LcrH and active immunity against plague
20. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague
21. The Yersinia Yop virulon: LcrV is required for extrusion of the translocators YopB and YopD
22. WEHI-13VAR: A stable and sensitive variant of WEHI 164 clone 13 fibrosarcoma for tumor necrosis factor bioassay
23. Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway
24. Assembly and function of type III secretory systems
25. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation
26. LcrV is a channel size-determining component of the Yop effector translocon of Yersinia
27. Cytokines and anticytokines in the pathogenesis of sepsis
28. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin
29. Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa
30. Correlation between opsonic activity for various microorganisms and composition of gammaglobulin preparations for intravenous use
31. 2 and Fab after intravenous administration in the rat
32. Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors
33. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial: The E5 Sepsis Study Group
34. Treatment of septic shock with human monoclonal antibody HA-IA: A randomized, double-blind, placebo-controlled trial: CHESS Trial Study Group